The majority of cancers (98.8%) were invasive ductal carcinomas: 16 (19.8%) were HR+/HER2− tumors, 8 (9.9%) were HR−/HER2+, and 16 (19.8%) were triple-positive and triple-negative, respectively. Here, ERBB2 is linked to invasive ductal breast carcinoma.